[1]阮长龙,廖应英,孙泽群.胃肠胰神经内分泌肿瘤早期诊断血清标志物研究进展[J].陕西医学杂志,2021,50(12):1602-1604,封3.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.034]
　RUAN Changlong,LIAO Yingying,SUN Zequn.Research progress on serum markers for early diagnosis of gastroenteropancreatic neuroendocrine neoplasms[J].,2021,50(12):1602-1604,封3.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.034]
点击复制

胃肠胰神经内分泌肿瘤早期诊断血清标志物研究进展
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年12期
页码:
1602-1604,封3
栏目:
综 述
出版日期:
2021-12-05

文章信息/Info

Title:
Research progress on serum markers for early diagnosis of gastroenteropancreatic neuroendocrine neoplasms
作者:
阮长龙1; 廖应英2; 孙泽群2
(1.锦州医科大学十堰市人民医院研究生培养基地,湖北 十堰 442099; 2.十堰市人民医院消化内科,湖北 十堰 442099)
Author(s):
RUAN Changlong; LIAO Yingying; SUN Zequn
(Graduate Training Base,Shiyan Renmin Hospital,Jinzhou Medical University,Shiyan 442099,China)
关键词:
胃肠胰神经内分泌肿瘤;  血清标志物;  嗜铬粒蛋白A;  神经元特异性烯醇化酶;  胰多肽;  嗜铬粒蛋白B;  早期诊断
Keywords:
Gastroenteropancreatic neuroendocrine neoplasms;  Serum markers;  Chromogmnin A;  Neuron-specific enolase;  Pancreatic polypeptide;  Chromogmnin B;  Early diagnosis
分类号:
R 739.4
DOI:
DOI:10.3969/j.issn.1000-7377.2021.12.034
文献标志码:
A
摘要:
胃肠胰神经内分泌肿瘤(GEP-NENs)较为少见,除少部分功能性肿瘤可分泌激素并引起类癌综合征外,大多数患者症状不典型,早期诊断较为困难,确诊时多伴有远处转移,因此寻找一组对GEP-NENs具有早期诊断价值的血清标志物,对提高诊断及判断预后至关重要。神经内分泌肿瘤(NENs)能够分泌多肽、胺类及蛋白类物质进入血液循环,研究显示检测这些物质水平对早期诊断GEP-NENs有一定价值。这些血清标志物包括嗜铬粒蛋白A(CgA)、神经元特异性烯醇化酶(NSE)、胰多肽(PP)、CgB等。现对它们在GEP-NENs早期诊断中的国内外研究进展进行综述。
Abstract:
Gastroenteropancreatic neuroendocrine tumors(GEP-NENs)are relatively rare.Except for a small number of functional tumors that can secrete hormones and cause carcinoid syndrome,most patients have atypical symptoms.Early diagnosis is difficult,and the diagnosis is often accompanied by distant locations metastasis,so finding a set of serum markers with early diagnostic value for GEP-NENs is very important to improve diagnosis and judge prognosis.Neuroendocrine tumors(NENs)can secrete peptides,amines and proteins into the blood circulation,and studies have shown that detecting the levels of these substances has certain value in the early diagnosis of GEP-NENs.These serum markers include chromogranin A(CgA),neuron-specific enolase(NSE),pancreatic polypeptide(PP),CgB,etc.Now the domestic and foreign research progress of them in the early diagnosis of GEP-NENs is reviewed.

参考文献/References:

[1] Modlin IM,Gustafsson BI,Moss SF,et al.Chromogranin A:Biological function and clinical utility in neuro endocrine tumor disease[J].Annals of Surgical Oncology,2010,17(9):2427-2443.
[2] Hofland J,Zandee WT,Herder WW.Role of biomarker tests for diagnosis of neuroendocrine tumours[J].Nat Rev Endocrinol,2018,14(11):656-669.
[3] Kanakis G,Kaltsas G.Biochemical markers for gastroenteropancreatic neuroendocrine tumours(GEP-NETs)[J].Best Practice & Research Clinical Gastroenterology,2012,26(6):791-802.
[4] Zhang C,Huang Y,Long J,et al.Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression[J].Oncol Lett,2019,17(2):1497-1504.
[5] 代伟宏.血清CgA对于胃肠胰神经内分泌肿瘤的诊断性Meta分析[D].沈阳:中国医科大学,2018.
[6] Janson ET,Knigge U,Dam G,et al.Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms[J].Acta Oncol,2021,60(7):931-941.
[7] 吴 俊,卢仁泉,郭 林.血清嗜铬粒蛋白A检测在神经内分泌肿瘤中的应用价值[J].检验医学,2019,34(2):122-125.
[8] 张年庆,谢方丽,刘思忆,等.嗜铬粒蛋白A水平与消化系统神经内分泌肿瘤肝转移临床关系的探讨[J].淮海医药,2019,37(2):130-132.
[9] 王钰虹,林 原,薛 玲,等.血清嗜铬素A在胃肠胰神经内分泌肿瘤临床诊断和疗效评价中的应用[J].中华消化杂志,2013,33(8):532-537.
[10] 刘 晗.血清CgA在胃肠胰神经内分泌肿瘤临床诊断和疗效评价中的应用[J].医药前沿,2015,5(31):159-160.
[11] Papantoniou D,Grönberg M,Landerholm K,et al.Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2[J].Endocrine,2021,72(3):893-904.
[12] Dam G,Grnbak H,Sorbye H,et al.Prospective study of chromogranin A as a predictor of progression in patients with pancreatic,small-intestinal,and unknown primary neuroendocrine tumors[J].Neuroendocrinology,2020,110(3-4):217-224.
[13] Marotta V,Zatelli MC,Sciammarella C,et al.Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms:More flaws than fame[J].Endocrine-Related Cancer,2018,25(1):11-29.
[14] 王丽恒,李梦竹,曾 跃.神经元特异性烯醇化酶的临床应用及研究进展[J].医学综述,2018,24(12):2301-2305.
[15] 韦 莉,王 敏.血清NSE在无功能性胰腺神经内分泌肿瘤诊断及鉴别诊断中的价值[J].国际检验医学杂志,2021,42(11):1349-1352.
[16] Lv Y,Han X,Zhang C,et al.Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs[J].Endocrine Connections,2018,7(1):169-178.
[17] Niederle B,Pape UF,Costa F,et al.ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum[J].Neuroendocrinology,2016,103(2):125-138.
[18] Li Y,Wu Z,Xu Q,et al.Development and validation of novel nomograms using serum tumor markers for the prediction of preoperative histologic grades in gastroenteropancreatic neuroendocrine tumors[J].Frontiers in Oncology,2021,11:681149.
[19] 王 军,李 杭,李国梁,等.血清肿瘤标志物在胃肠胰神经内分泌肿瘤中的表达情况[J].中国慢性病预防与控制,2018,26(10):783-786.
[20] 黄亮星,贺东红.脑出血患者神经内分泌因子表达水平与脑出血量及认知功能相关性研究[J].陕西医学杂志,2020,49(4):439-441.
[21] Sliwińska-Mossoń M,Marek G,Milnerowicz H.The role of pancreatic polypeptide in pancreatic diseases[J].Advances in Clinical and Experimental Medicine,2017,26(9):1447-1456.
[22] Qiu W,Christakis I,Silva A,et al.Utility of chromogranin A,pancreatic polypeptide,glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients[J].Clinical Endocrinology,2016,85(3):400-407.
[23] 李远良,王 鑫,王 萍,等.嗜铬粒蛋白B在晚期神经内分泌肿瘤中的应用[J].中国医学前沿杂志:电子版,2021,13(5):40-44.
[24] Adaway JE,Dobson R,Walsh J,et al.Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement[J].Ann Clin Biochem,2016,53(5):554-560.
[25] Fernandez CJ,Agarwal M,Pottakkat B,et al.Gastroenteropancreatic neuroendocrine neoplasms:A clinical snapshot[J].World Journal of Gastrointestinal Surgery,2021,13(3):231-255.
[26] Rizzo FM,Meyer T.Liquid biopsies for neuroendocrine tumors:Circulating tumor cells,DNA,and microRNAs[J].Endocrinology and Metabolism Clinics of North America,2018,47(3):471-483.
[27] Khan MS,Kirkwood AA,Tsigani T,et al.Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms[J].Clinical Cancer Research,2016,22(1):79-85.
[28] Nagtegaal ID,Odze RD,Klimstra D,et al.The 2019 WHO classification of tumours of the digestive system[J].Histopathology,2019,76(2):182-188.
[29] Zakka K,Nagy R,Drusbosky L,et al.Blood-based next-generation sequencing analysis of neuroendocrine neoplasms[J].Oncotarget,2020,11(19):1749-1757.
[30] Malczewska A,Oberg K,Kos-Kudla B.NETest is superior to chromogranin A in neuroendocrine neoplasia:A prospective ENETS CoE analysis[J].Endocrine Connections,2021,10(1):110-123.
[31] Zimmermann N,Knief J,Kacprowski T,et al.Micro RNA analysis of gastroenteropancreatic neuroendocrine tumors and metastases[J].Oncotarget,2018,9(47):28379-28390.

备注/Memo

备注/Memo:
基金项目:湖北省十堰市引导性科研项目(21Y62)
更新日期/Last Update: 2021-12-07